Journal of Hematological Oncology
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes.
CBC (complete blood count)
|Red blood cell count||Male: 4.35-5.65 trillion cells/L*|
(4.32-5.72 million cells/mcL**)Female: 3.92-5.13 trillion cells/L
(3.90-5.03 million cells/mcL)
|Hemoglobin||Male: 13.2-16.6 grams/dL***|
Female: 11.6-15 grams/dL
|Hematocrit||Male: 38.3-48.6 percent|
Female: 35.5-44.9 percent
|White blood cell count||3.4-9.6 billion cells/L|
(3,400 to 9,600 cells/mcL)
|Platelet count||Male: 135-317 billion/L|
(135,000 to 317,000/mcL)
Female: 157-371 billion/L